发明授权
US07279464B2 DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
失效
编码CEA和CD40配体的DNA疫苗及其使用方法
- 专利标题： DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
- 专利标题（中）： 编码CEA和CD40配体的DNA疫苗及其使用方法
-
申请号： US11195506申请日： 2005-08-02
-
公开(公告)号： US07279464B2公开(公告)日： 2007-10-09
- 发明人: Rong Xiang , Ralph A. Reisfeld
- 申请人： Rong Xiang , Ralph A. Reisfeld
- 申请人地址： US CA La Jolla
- 专利权人： The Scripps Research Institute
- 当前专利权人： The Scripps Research Institute
- 当前专利权人地址： US CA La Jolla
- 代理机构： Olson & Hierl, Ltd.
- 主分类号： A61K35/00
- IPC分类号： A61K35/00 ; A61K38/43 ; A61K48/00 ; C12N15/63 ; C12N15/00
摘要：
A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. In a method embodiment, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. A preferred method embodiment includes the additional step of treating the mammal with recombinant antibody fusion protein huKS1/4-IL2 to enhance the immune response effectiveness of the vaccine.
公开/授权文献
信息查询
